ARIA ARIAD Pharmaceuticals, Inc.

+0  (0%)
Previous Close 23.99
Open 0.00
Price To book 0.00
Market Cap N/A
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 9,913,520

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

To be acquired by Takeda. Deal to close by the end of February 2017.
To be acquired

Latest News

  1. Former Ariad CEO joins a familiar face on board of The Medicines Co., hinting at a sale
  2. Amgen's Blincyto sBLA Secures FDA Priority Review
  3. Who Is Incyte Collaborating With?
  4. Two Great Stock Ideas in the IBB Biotech ETF
  5. ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib
  6. Why Ariad Pharmaceuticals Stock Nearly Doubled in January
  7. Ariad Submits Marketing Application to EU Agency
  8. ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
  9. Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan
  10. Ariad mum on layoffs in letter to employees: ‘It’s business as usual’
  11. Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC
  12. Ariad played hardball to boost Takeda buyout price, federal filings show
  13. Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017
  14. Can The Uptrend Continue for ARIAD Pharmaceuticals (ARIA)?
  15. 5 Expensive Drugs That Could End Up in Trump's Crosshairs
  16. Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders
  17. Jazz Begins Phase III Study for Label Expansion of Defitelio
  18. Becton, Dickinson Commercially Launches Precise WTA Kits
  19. These 3 Stocks Have Doubled Since Election Day
  20. ARIAD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of ARIAD Pharmaceuticals, Inc. (ARIA) Over the Proposed Sale of the Company to Takeda Pharmaceutical Company Limited